EXEL


Exelixis Partners With Merck KGaA And Pfizer For STELLAR-001 Clinical Trial

Exelixis, an oncology-focused biotechnology company, entered into a clinical trial collaboration and supply agreement with Germany-based Merck KGaA, a science and technology company, …

Why Did Farallon Capital Get Out of These 3 Biotech Stocks?

Since 1986, Farallon Capital has built a proven record for success, mainly from steady hands at the helm and consistent returns for investors. …

Exelixis, Inc.’s (EXEL) RCC Treatment Gets Early FDA Approval

Exelixis, Inc. (NASDAQ:EXEL) said on Tuesday that the FDA approved its CABOMETYX tablets, for the expanded indication of patients with advanced renal cell carcinoma …

Top Analyst Pounds the Table on Exelixis, Inc. (EXEL)

Cowen’s Eric Schmidt sees an extra several hundred million dollars in sales for EXEL in HCC market.

Why Exelixis, Inc. (EXEL) Shares Took Off Today

Exelixis, Inc. (NASDAQ:EXEL) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 30% upturn.

Marshall Wace Pulled Back Holding in Intercept Pharmaceuticals Inc (ICPT), Optimistic About Valeant Pharmaceuticals Intl Inc (VRX) and Exelixis, Inc. (EXEL)

A first glance at this hedge fund’s strategic Q2 moves in biotech sector.

Exelixis, Inc. (EXEL) Focuses on CABOMETYX’s Label Expansion

Exelixis, Inc. (NASDAQ:EXEL) announced this morning that it has completed the submission of a supplemental New Drug Application (sNDA) to FDA for Cabometyx …

Dynavax Technologies Corporation (DVAX) Has the Market Buzzing with Heplisav Approval at the Finish Line, Exelixis, Inc. (EXEL) Refractory RCC Drug Going Strong in its Launch

Dynavax’s Advantage Weighs Towards Heplisav’s Benefits Dynavax Technologies Corporation (NASDAQ:DVAX) shares are racing 5% today after releasing second-quarter earnings. However, this rocket momentum …

William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL)

Sarepta’s $12+ Million 2Q Beat Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts